[
  {
    "ts": "2025-12-18T19:00:00+00:00",
    "headline": "Intel, Paramount are some of Wall Street's best comebacks of 2025",
    "summary": "Paramount Skydance (PSKY), Intel (INTC), and Estée Lauder (EL) are just some of the S&P 500 (^GSPC) components that gained in 2025, rebounding from negative returns in 2024. Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks in Translation podcast, takes a closer look at some of 2025's best comebacks. Catch more Stocks in Translation, with new episodes every Tuesday and Thursday. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finance.yahoo.com/video/intel-paramount-wall-streets-best-190000152.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "e51aaf05-fcfa-31e6-ac51-759e4b1a9181",
      "content": {
        "id": "e51aaf05-fcfa-31e6-ac51-759e4b1a9181",
        "contentType": "VIDEO",
        "title": "Intel, Paramount are some of Wall Street's best comebacks of 2025",
        "description": "<p>Paramount Skydance (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/PSKY\">PSKY</a>), Intel (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/INTC\">INTC</a>), and Estée Lauder (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/EL\">EL</a>) are just some of the S&P 500 (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/%5EGSPC\">^GSPC</a>) components that gained in 2025, rebounding from negative returns in 2024.</p>\n<p>Yahoo Finance Markets and Data Editor <a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/author/jared-blikre/\">Jared Blikre</a>, who also hosts Yahoo Finance's <a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/videos/series/stocks-in-translation/\">Stocks in Translation podcast</a>, takes a closer look at some of 2025's best comebacks.</p>\n<p>Catch more <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/videos/series/stocks-in-translation/\">Stocks in Translation</a>, with new episodes every Tuesday and Thursday.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Paramount Skydance (PSKY), Intel (INTC), and Estée Lauder (EL) are just some of the S&P 500 (^GSPC) components that gained in 2025, rebounding from negative returns in 2024. Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks in Translation podcast, takes a closer look at some of 2025's best comebacks. Catch more Stocks in Translation, with new episodes every Tuesday and Thursday. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
        "pubDate": "2025-12-18T19:00:00Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/99c6f720-dc3b-11f0-b686-641e361ba176",
          "originalWidth": 4896,
          "originalHeight": 2756,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ItYpG6wtWt_liPojX0_98A--~B/aD0yNzU2O3c9NDg5NjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/99c6f720-dc3b-11f0-b686-641e361ba176.cf.webp",
              "width": 4896,
              "height": 2756,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IVPtHUnyt5KvreiO_SYqNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/99c6f720-dc3b-11f0-b686-641e361ba176.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/intel-paramount-wall-streets-best-190000152.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/intel-paramount-wall-streets-best-190000152.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALB"
            },
            {
              "symbol": "ALB-PA"
            },
            {
              "symbol": "EL"
            },
            {
              "symbol": "APTV"
            },
            {
              "symbol": "DLTR"
            },
            {
              "symbol": "IDXX"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "DG"
            },
            {
              "symbol": "HII"
            },
            {
              "symbol": "NUE"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T14:55:00+00:00",
    "headline": "Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?",
    "summary": "DHR sees Biotechnology core revenues rise 6.5% in Q3 2025, fueled by bioprocessing demand, with approximately 5% growth expected in Q4.",
    "url": "https://finance.yahoo.com/news/strength-biotechnology-unit-continue-drive-145500600.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6b4257e4-1284-354b-aef6-37d20299aae7",
      "content": {
        "id": "6b4257e4-1284-354b-aef6-37d20299aae7",
        "contentType": "STORY",
        "title": "Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?",
        "description": "",
        "summary": "DHR sees Biotechnology core revenues rise 6.5% in Q3 2025, fueled by bioprocessing demand, with approximately 5% growth expected in Q4.",
        "pubDate": "2025-12-18T14:55:00Z",
        "displayTime": "2025-12-18T14:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6f73e5864dcc48a38339373784f53a25",
          "originalWidth": 620,
          "originalHeight": 496,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1prlNOIsV7tqm_mhXTIgbw--~B/aD00OTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f73e5864dcc48a38339373784f53a25.cf.webp",
              "width": 620,
              "height": 496,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_nG8ehaIyD5XN83vBGSwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f73e5864dcc48a38339373784f53a25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strength-biotechnology-unit-continue-drive-145500600.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strength-biotechnology-unit-continue-drive-145500600.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DHR"
            },
            {
              "symbol": "LH"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T12:32:00+00:00",
    "headline": "2 Dividend Stocks to Buy for 2026 and Beyond",
    "summary": "The healthcare sector is a great place to find quality income stocks, and these two appear to be strong picks.",
    "url": "https://www.fool.com/investing/2025/12/18/2-dividend-stocks-to-buy-for-2026-and-beyond/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1cd67753-f5c5-3567-92a0-9f2adfd7aaf8",
      "content": {
        "id": "1cd67753-f5c5-3567-92a0-9f2adfd7aaf8",
        "contentType": "STORY",
        "title": "2 Dividend Stocks to Buy for 2026 and Beyond",
        "description": "",
        "summary": "The healthcare sector is a great place to find quality income stocks, and these two appear to be strong picks.",
        "pubDate": "2025-12-18T12:32:00Z",
        "displayTime": "2025-12-18T12:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/6d74ca845e2240bac12dac2426e73b11",
          "originalWidth": 1400,
          "originalHeight": 828,
          "caption": "Pharmacist talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fuwKbaDNUnxDsfTwVWT5BA--~B/aD04Mjg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/6d74ca845e2240bac12dac2426e73b11.cf.webp",
              "width": 1400,
              "height": 828,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b9l26fKkHIUBS_yiqH547Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/6d74ca845e2240bac12dac2426e73b11.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/18/2-dividend-stocks-to-buy-for-2026-and-beyond/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-dividend-stocks-buy-2026-123200620.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T02:15:38+00:00",
    "headline": "Higher Guidance and Big Impairment Charges Might Change The Case For Investing In CVS Health (CVS)",
    "summary": "In December 2025, CVS Health raised its 2025 guidance to at least US$400.0 billion in revenue and higher GAAP operating income, while also forecasting a US$5.73 billion goodwill impairment. At the same time, CVS Health issued new 2026 guidance, signaling a reset of reported earnings around large non-cash charges amid mounting regulatory scrutiny and its Healthy 2030 sustainability agenda. We’ll now examine how CVS Health’s higher revenue and earnings guidance, despite sizable goodwill...",
    "url": "https://finance.yahoo.com/news/higher-guidance-big-impairment-charges-021538374.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dbeacab2-09e6-3b7a-b719-1c34b46ba15b",
      "content": {
        "id": "dbeacab2-09e6-3b7a-b719-1c34b46ba15b",
        "contentType": "STORY",
        "title": "Higher Guidance and Big Impairment Charges Might Change The Case For Investing In CVS Health (CVS)",
        "description": "",
        "summary": "In December 2025, CVS Health raised its 2025 guidance to at least US$400.0 billion in revenue and higher GAAP operating income, while also forecasting a US$5.73 billion goodwill impairment. At the same time, CVS Health issued new 2026 guidance, signaling a reset of reported earnings around large non-cash charges amid mounting regulatory scrutiny and its Healthy 2030 sustainability agenda. We’ll now examine how CVS Health’s higher revenue and earnings guidance, despite sizable goodwill...",
        "pubDate": "2025-12-18T02:15:38Z",
        "displayTime": "2025-12-18T02:15:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b281afd73848ff2f053c086d0c5a15e9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/az3maBuei.SURwtIZ4ic4A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b281afd73848ff2f053c086d0c5a15e9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cKBGpv3s0tfaq.7ZzVUgPA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b281afd73848ff2f053c086d0c5a15e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/higher-guidance-big-impairment-charges-021538374.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/higher-guidance-big-impairment-charges-021538374.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]